http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0608429-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2006-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33aa401f736c46fb0acd0f3329a4c5ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_612e666d59632e47f82f1c98711fa232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7dc63c3842b29454a50e6a2e6f499ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afe7d087b4947212e110a840eb5c62d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f87c7f720d4a59975613874c4b439995 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1ea5ebfdccc40008e72b5b5085a8c0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a387efc401305898036bbbcfb030ad7f |
| publicationDate | 2009-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0608429-A2 |
| titleOfInvention | method and kit for predicting or evaluating the effectiveness of treating a solid tumor in a patient of interest; and method for identifying markers that are prognostic for a solid tumor |
| abstract | METHOD AND KIT FOR PROGNOSTICS OR EVALUATION OF THE EFFICIENCY OF TREATMENT OF A SOLID TUMOR IN A PATIENT OF INTEREST; AND METHOD FOR IDENTIFYING MARKERS THAT ARE PROGNOSTICS OF A SOLID TUMOR. The present invention provides methods, systems and equipment for predicting or evaluating the treatment of solid tumors. Genetic markers that are predictive of solid tumors may be identified in accordance with the present invention. Each genetic marker has altered expression patterns in PBMCs of patients with solid tumors following initiation of anticancer treatment, and the magnitude of these changes correlates with the clinical outcomes of these patients. In one embodiment, a Cox proportional hazards model is used to determine correlations between clinical outcomes of patients with CCR and changes in gene expression in PBMCs of these patients during CCI-779 treatment. Non-limiting examples of genes identified by the Cox model are shown in Tables 4A, 4B, 5A and 55. These genes can be used as surrogate markers for CCR prognosis. They can also be used as pharmacogenomic indicators for the efficacy of CCI-779 or other anti-cancer drugs. |
| priorityDate | 2005-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918289 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480166 |
Total number of triples: 22.